scholarly journals Furegrelate, a Thromboxane Synthase Inhibitor, Blunts the Development of Pulmonary Arterial Hypertension in Neonatal Piglets

2012 ◽  
Vol 2 (2) ◽  
pp. 193-200 ◽  
Author(s):  
Dinesh K. Hirenallur-S ◽  
Neil D. Detweiler ◽  
Steven T. Haworth ◽  
Jeaninne T. Leming ◽  
John B. Gordon ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Thromboxane Synthase ◽  
Neonatal Piglets ◽  
Thromboxane Synthase Inhibitor ◽  
Pulmonary Arterial ◽  
Synthase Inhibitor

scholarly journals Oral Administration of a Novel Long-Acting Prostacyclin Agonist With Thromboxane Synthase Inhibitory Activity for Pulmonary Arterial Hypertension

2013 ◽  
Vol 77 (8) ◽  
pp. 2127-2133 ◽  
Author(s):  
Atsuhiro Nakamura ◽  
Noritoshi Nagaya ◽  
Hiroaki Obata ◽  
Katsuya Sakai ◽  
Yoshiki Sakai ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Oral Administration ◽  
Arterial Hypertension ◽  
Inhibitory Activity ◽  
Thromboxane Synthase ◽  
Pulmonary Arterial ◽  
Long Acting

A Comparison of Human Pulmonary Arterial and Venous Prostacyclin and Thromboxane Synthesis- Effect of a Thromboxane Synthase Inhibitor

1984 ◽  
Vol 51 (02) ◽  
pp. 257-260 ◽  
Author(s):  
A J Carter ◽  
J A Bevan ◽  
S P Hanley ◽  
W E Morgan ◽  
D R Turner
Keyword(s):  
Thoracic Surgery ◽  
Pulmonary Arteries ◽  
Significant Inhibition ◽  
Thromboxane B2 ◽  
Thromboxane Synthase ◽  
Paired Samples ◽  
Thromboxane Synthase Inhibitor ◽  
Pulmonary Arterial ◽  
Synthase Inhibitor ◽  
Arteries And Veins

SummaryThe amounts of 6-keto-prostaglandin F1α (6-keto-PGF1α) and thromboxane B2 (TxB2) produced by the endothelial surfaces of paired samples of human pulmonary arteries and veins, obtained from patients undergoing thoracic surgery, were measured. The amounts of 6-keto-PGF1α and TxB2 produced by arteries compared with veins were not different. However, both arteries and veins produced more 6-keto-PGFlα than TxB2, the ratio being approximately 7.5:1 for both. 6-keto-PGFlα synthesis by arteries was significantly correlated with that produced by veins but the relative amounts of TxB2 were not correlated. 6-keto-PGFlα synthesis was correlated with TxB2 synthesis for veins but not for arteries. 8 of the 12 arterial samples exhibited some degree of intimal fibrosis.Incubation with the thromboxane synthase inhibitor, dazoxiben, caused a significant inhibition of vascular TxB2 synthesis and a significant increase in 6-keto-PGFlα synthesis. In 3 of the 5 cases the increase in 6-keto-PGFlα was too large to be explained by the fall in TxB2.

Thromboxane synthase inhibition and cardiopulmonary function during endotoxemia in sheep

1991 ◽  
Vol 71 (4) ◽  
pp. 1376-1381 ◽  
Author(s):  
K. Fujioka ◽  
K. Sugi ◽  
T. Isago ◽  
J. T. Flynn ◽  
L. D. Traber ◽  
...  
Keyword(s):  
Cardiac Index ◽  
Systolic Pressure ◽  
Lymph Flow ◽  
Thromboxane Synthase ◽  
Thromboxane Synthase Inhibitor ◽  
Dimension Analysis ◽  
Pulmonary Arterial ◽  
Synthase Inhibitor ◽  
Lung Lymph ◽  
Lung Lymph Flow

We studied the cardiopulmonary response to endotoxin (lipopolysaccharide, LPS) in sheep with and without the administration of a thromboxane synthase inhibitor, OKY-046. The animals were instrumented for crystalographic dimension analysis of the left ventricle (LV) and for measurement of LV, aortic, left atrial, and pulmonary arterial pressures and cardiac index, as well as lung lymph flow. They received 1.0 micrograms/kg of Escherichia coli LPS with (n = 8) and without (n = 8) OKY-046 (10 mg/kg bolus, then 10 micrograms.kg-1.min-1). OKY-046 prevented the increase of pulmonary arterial pressure and the decrease of cardiac index that occurred during the early phase of endotoxemia. Between 8 and 12 h after LPS, cardiac index increased from 6.8 +/- 0.7 to 8.9 +/- 0.51.min-1.m-2. Concomitantly, the end-systolic pressure-diameter relationship (ESPDR, sensitive myocardial contractility index) significantly decreased from 14.7 +/- 0.6 to 7.7 +/- 0.7. Other indexes of the LV contractility (+dP/dtmax) were also reduced. OKY-046 prevented the decreases of ESPDR and +dP/dtmax. OKY-046 also attenuated the increased lung lymph flow changes seen with LPS.

732 Responsiveness to inhaled nitric oxide in patients with pulmonary arterial hypertension and right heart failure

2006 ◽  
Vol 5 (1) ◽  
pp. 171-171
Author(s):  
P PODOLEC ◽  
M KAZNICAWIATR ◽  
M HLAWATY ◽  
P WILKOLEK ◽  
Z PODOLEC ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Heart Failure ◽  
Inhaled Nitric Oxide ◽  
Right Heart ◽  
Pulmonary Arterial

123 Prevalence of pulmonary arterial hypertension and echocardiographic signs of right heart failure in HIV infected patients

2007 ◽  
Vol 6 (1) ◽  
pp. 30-30
Author(s):  
C BUHR ◽  
N REINSCH ◽  
P KRINGS ◽  
H KAELSCH ◽  
T KONORZA ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Heart Failure ◽  
Right Heart ◽  
Pulmonary Arterial

FDA: No to Revatio for Kids With Pulmonary Arterial Hypertension

2012 ◽  
Vol 42 (16) ◽  
pp. 10
Author(s):  
Frances Correa
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document